Clinic
Memorial Health System of East Texas
Memorial Health System of East Texas was paid $8.62M by Medicaid between Oct 2020 and Nov 2024, across 86 billing codes. Its largest line is 99284, emergency room visit (serious) — 35% of everything it billed.
33Billing provider infoMEMORIAL HEALTH SYSTEM OF EAST TEXAS
LUFKIN, TX 75904
LUFKIN, TX 75904
33aNPI1396746129assigned 08/02/2005
33bProvider typeAmbulatory Surgical Clinic/Center
28Total paid$8.62M
24GClaims88,365
24DCodes billed86
24AFirst – last monthOct 2020 – Nov 2024
Compared with peers
Next to other Ambulatory Surgical Clinic/Center providers in Texas
Rank by total paid#50 of 320
Median peer was paid$205K
This provider vs. median42×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 1,997 | $122K | |
| 2021 | 24,442 | $1.71M | |
| 2022 | 29,075 | $3.06M | |
| 2023 | 22,081 | $2.79M | |
| 2024incomplete | 10,770 | $931K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 35% | 6,711 | 6,219 | $3.03M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 23% | 8,633 | 7,920 | $1.96M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 17% | 3,420 | 3,114 | $1.51M |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 6.7% | 694 | 663 | $574K |
| 71045 | Radiologic examination, chest; single view | 3.2% | 3,465 | 3,176 | $280K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.1% | 1,297 | 1,249 | $265K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.2% | 2,181 | 1,844 | $100K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | 1.1% | 179 | 173 | $97K |
| 80047 | <1% | 5,777 | 5,204 | $80K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,617 | 2,979 | $78K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 9,132 | 7,740 | $64K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 354 | 74 | $55K |
74 more codes
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 307 | $55K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 328 | $43K |
| 87486 | <1% | 508 | $34K | |
| 87581 | <1% | 508 | $34K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 541 | $32K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 294 | $31K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 228 | $27K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,166 | $27K |
| 59025 | Fetal non-stress test | <1% | 225 | $21K |
| 87430 | <1% | 638 | $19K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 98 | $18K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 12 | $17K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 68 | $15K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 917 | $15K |
| 80076 | <1% | 1,867 | $13K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 425 | $12K |
| 81001 | <1% | 3,976 | $10K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 284 | $9K |
| 87070 | <1% | 614 | $7K | |
| 87077 | <1% | 1,790 | $6K | |
| 80053 | Comprehensive metabolic panel | <1% | 2,122 | $6K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,708 | $6K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 250 | $5K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 55 | $5K |
| 81025 | <1% | 390 | $4K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 467 | $4K |
| 84484 | <1% | 1,201 | $4K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 197 | $4K |
| 83880 | <1% | 432 | $3K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 40 | $3K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 18 | $3K |
| 83690 | <1% | 762 | $3K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,192 | $3K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 197 | $2K |
| 87186 | <1% | 840 | $2K | |
| CP007 | <1% | 60 | $2K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,325 | $2K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 198 | $2K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 507 | $2K |
| 81003 | <1% | 687 | $2K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,124 | $2K |
| 87081 | <1% | 101 | $2K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 14 | $1K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 318 | $1K |
| 76770 | <1% | 41 | $1K | |
| 96376 | <1% | 25 | $967.47 | |
| 83735 | <1% | 571 | $914.02 | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 16 | $865.35 |
| 85610 | <1% | 799 | $824.79 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 8,680 | $778.44 |
| 84703 | <1% | 94 | $729.74 | |
| 77080 | <1% | 72 | $681.24 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 249 | $661.51 |
| 85730 | <1% | 396 | $573.81 | |
| 87040 | <1% | 51 | $456.44 | |
| 83605 | <1% | 164 | $439.41 | |
| 87420 | <1% | 19 | $344.35 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 52 | $273.66 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 78 | $270.88 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 30 | $229.77 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 45 | $166.78 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 42 | $126.62 |
| 84702 | <1% | 17 | $115.06 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 28 | $62.02 |
| 86901 | <1% | 31 | $46.89 | |
| 80061 | Lipid panel | <1% | 46 | $40.32 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 79 | $39.91 |
| 85027 | <1% | 112 | $29.09 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 30 | $13.30 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 333 | $0.00 |
| A9270 | Non-covered item or service | 0% | 750 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 13 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 13 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 30 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGLASS, MEGAN (REIMBURSEMENT ANALYST)
| Provider | Location | Paid |
|---|---|---|
| Memorial Hospital of Polk County | Livingston, TX | $10.49M |
| Memorial Medical Center San Augustine | San Augustine, TX | $694K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.